IX Biopharma Ltd
SGX:42C
Gross Margin
IX Biopharma Ltd
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| SG |
I
|
IX Biopharma Ltd
SGX:42C
|
15m SGD |
18%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
739.9B USD |
82%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
56%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
375.3B USD |
68%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
84%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
207.2B CHF |
74%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
192.4B CHF |
76%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
160.1B GBP |
82%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
203.6B USD |
78%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
68%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
144.3B USD |
75%
|
IX Biopharma Ltd
Glance View
iX Biopharma Ltd. engages in the development and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. The firm is focused on the development and commercialization of therapies for diseases of the central nervous system using patent protected formulations for sublingual delivery. The company developed a patented drug delivery platform technology, WaferiX. WaferiX delivers drug sublingually via the mucosa for better absorption, faster onset of action and predictable effect. Its delivery platform is particularly useful for drug repurposing. The firm operates in two segments, namely Specialty Pharmaceutical and Nutraceutical segments. Specialty Pharmaceutical primary business activities are the development, manufacturing and sale of pharmaceutical and nutraceutical products. Nutraceutical primary business activities are the sale of nutraceutical products. The firm's pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on IX Biopharma Ltd's most recent financial statements, the company has Gross Margin of 18.4%.
You don't have any saved screeners yet